FRANCE - Diatos raises further EUR 9.4m

The EUR 9.4m were provided by GIMV(Belgium), Crédit Agricole Private Equity (France), InterWest Partners (United States), Innoven Partenaires (France), Sofinnova Partners (France), Biotech Fund Flanders (Belgium), AGF Private Equity (France), NIF SMBC (Japan), Sopartec (Belgium), and SGAM (France).

The new injection of funding will allow Diatos to further develop its leading clinical products. The paclitaxel depot formulated polymer gel DTS-301, having recently completed a Phase IIa and poised to enter Phase IIb/III in Esophageal cancer, the doxorubicin prodrug DTS 201, having recently completed a Phase I in solid tumors and poised to enter Phase II; as well as to expand its product pipeline with the launch of DTS-108, a second generation Irinotecan, in GLP preclinical toxicology studies and the continuous focus on generating new TSP-based drugs.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• France